FOI:2022/439

Response for time period 01/08/2022 to 31/10/2022 inclusive:

Please note that because of the combinations that have been asked for some patients may be double counted as they are on combinations that could fall into more than one category.

1.       In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:

·       Abemaciclib monotherapy – NIL – all use must be with an aromatase inhibitor or Fulvestrant

·       Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole) – Prescribed in Primary Care

·       Tamoxifen monotherapy – Prescribed in Primary Care

·       Abemaciclib + Tamoxifen – The Trust cannot answer as Abemaciclib is supplied by the Trust but any supporting hormone treatment is prescribed in Primary Care, and so the Trust does not have data on which combinations are used.

2.       In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:

·       Abemaciclib + Aromatase inhibitor (e.g. anastrozole, exemestane, letrozole) – 20

·       Taxane and/or Anthracycline (monotherapy or in combination) – 111

·       Any other active systemic anti cancer therapy –  144

3.       How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:

·       Anthracycline (e.g. doxorubicin or epirubicin) as a single agent – NIL

·       Atezolizumab +Nab-paclitaxel/Paclitaxel – <5

·       Pembrolizumab – NIL

·       Sacituzumab Govitecan – 5

·       Parp Inhibitors (Olaparib/Talazoparib) – NIL

·       Eribulin as a single agent or in combination – <5

·       Capecitabine as a single agent – NIL

·       Platinum (e.g. carboplatin or cisplatin) as a single agent – NIL

·       Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent – 9

·       Taxane and/or Anthracycline in combination – 73

·       Any other active systemic anti-cancer therapy – 63 

​​​​​​​